Campath-1H (alemtuzumab) is the most effective monoclonal antibody in single-agent use in B-cell chronic lymphocytic leukemia (CLL) with reported response rates of 33% to 70%. Combination therapy is now the conventional treatment for most hematologic malignancies. Monoclonal antibody treatments may sensitize tumor cells to subsequent chemotherapy. We report the combination of Campath-1H with fludarabine in patients with CLL refractory to each agent used singly. Six patients who had received a median of 8 courses of fludarabine (range, 4-10 courses) and 16 weeks of Campath-1H (range, 8-32 weeks) were treated. Five patients responded, including one who had a complete response by National Cancer Institute criteria. The responses observed were better in each patient than responses after each agent used singly. Complete morphologic bone marrow responses were seen in 3 patients, including eradication of disease measured by sensitive flow cytometry in 2. Campath-1H combined with fludarabine is a highly promising novel therapy for refractory CLL.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1182/blood.v99.6.2245 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optimizing Real-World Outcomes in High-Risk Relapsed/Refractory (r/r) DLBCL with CAR T Cell Therapy: A Vodcast and Case Example.
Oncol Ther
December 2024
Department of Hematology, Regional University Hospital, Málaga, Spain.
Chimeric antigen receptor (CAR) T-cell therapy is effective in the treatment of patients with diffuse large B cell lymphoma (DLBCL), even those with high-grade disease. However, it has a unique safety profile, including cytokine-release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), and robust management of these events are important to maximize benefits. The aim of this vodcast is to outline the management of a patient receiving CAR T-cell therapy for relapsed/refractory (r/r) DLBCL.
View Article and Find Full Text PDFImmunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis.
Cochrane Database Syst Rev
September 2024
IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Background: In recent years a broader range of immunomodulatory and immunosuppressive treatment options have emerged for people with progressive forms of multiple sclerosis (PMS). While consensus supports these options as reducing relapses, their relative benefit and safety profiles remain unclear due to a lack of direct comparison trials.
Objectives: To compare through network meta-analysis the efficacy and safety of alemtuzumab, azathioprine, cladribine, cyclophosphamide, daclizumab, dimethylfumarate, diroximel fumarate, fingolimod, fludarabine, glatiramer acetate, immunoglobulins, interferon beta 1-a and beta 1-b, interferon beta-1b (Betaferon), interferon beta-1a (Avonex, Rebif), laquinimod, leflunomide, methotrexate, minocycline, mitoxantrone, mycophenolate mofetil, natalizumab, ocrelizumab, ofatumumab, ozanimod, pegylated interferon beta-1a, ponesimod, rituximab, siponimod, corticosteroids, and teriflunomide for PMS.
Durable remission of refractory and advanced stage mycosis fungoides/sezary syndrome utilizing an "outpatient" alemtuzumab, fludarabine-based reduced intensity allogeneic hematopoietic cell transplantation.
Bone Marrow Transplant
December 2024
National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Alemtuzumab-based conditioning regimen before hematopoietic stem cell transplantation in patients with short telomere syndromes: a retrospective study of the SFGM-TC.
Bone Marrow Transplant
October 2024
Assistance Publique des Hôpitaux de Paris, Hôpital Saint-Louis, Service d'Hématologie Greffe de Moelle & Centre de référence national des aplasies médullaires acquises et constitutionnelles, Paris, France.
Article Synopsis
- HSCT is the only curative treatment for patients with short telomere syndromes and severe bone marrow failure or myeloid malignancies, but the effectiveness is influenced by their sensitivity to the conditioning regimen.
- In a study involving adults and adolescents treated with an alemtuzumab-based regimen, outcomes showed a low 2-year graft rejection-free survival (GRFS) rate for those with myeloid malignancies (20%) compared to other patients (57%).
- While the overall 2-year overall survival (OS) was quite favorable at 66%, the findings suggest that alternative treatment strategies may be necessary for patients with myeloid malignancies.
Allogeneic Hematopoietic Cell Transplant For Bone Marrow Failure or Myelodysplastic Syndrome in Dyskeratosis Congenita/Telomere Biology Disorders: Single-Center, Single-Arm, Open-Label Trial of Reduced-Intensity Conditioning Without Radiation.
Transplant Cell Ther
October 2024
Division of Pediatric Blood and Marrow Transplant & Cellular Therapy, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota. Electronic address:
Article Synopsis
- Dyskeratosis congenita/telomere biology disorders (DC/TBD) often lead to bone marrow failure, and although allogeneic hematopoietic cell transplant (alloHCT) can help, traditional conditioning methods can cause significant toxicity.
- A clinical trial compared the outcomes of reduced intensity conditioning (RIC) alloHCT to a prior trial that included total body irradiation (TBI) in patients with DC/TBD, focusing on less toxic methods to ensure successful engraftment.
- While both groups demonstrated comparable outcomes in acute and chronic graft-versus-host disease and no primary graft failures, the non-TBI cohort showed slower donor chimerism achievement, indicating a balance between conditioning intensity and patient safety.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!